- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04058314
Clinical Investigation of OMEGA Gemini Capsule, Model Gemini IV With an Approved Monofocal or Toric IOL
September 15, 2020 updated by: Omega Ophthalmics
Clinical Investigation of OMEGA Gemini Capsule, Model Gemini IV in Combination With a Commercially Available, FDA Approved Monofocal or Toric Intraocular Lens (The Gemini IV Trial)
This study is a prospective, randomized, controlled, paired eye, subject-masked design.
Study Overview
Detailed Description
Subjects will be randomly assigned to which eye will receive the Omega capsule Gemini IV with an approved monofocal or Toric intraocular lens. Fellow eyes will receive an approved monofocal or Toric IOL (no Omega capsule).
Eyes randomized to receive the Gemini capsule will be eligible to have a secondary procedure (post 1-month postoperative visit) to correct refractive error.
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
San José, Costa Rica
- Clinica 20/20
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 40 years of age or older at the time of surgery diagnosed with bilateral cataracts
- Able to understand and sign an informed consent
- Willing and able to complete all study visits and assessments required for the study
- Calculated lens power within the available range
- Corrected distance visual acuity is equal to or worse than 20/40 in each eye with or without a glare source present
- Bilateral cataracts eligible for extraction by phacoemulsification and capsular bag fixated IOL implantation
- Potential postop visual acuity of 20/25 or better in the judgment of the surgeon
- Preoperative corneal astigmatism of 4.0 D or less with normal corneal topography
- Clear intraocular media other than cataract
- Preop endothelial cell density of 2000 cells/mm2 or more
Exclusion Criteria:
- Subject's best corrected vision is light perception or no light perception in either eye
- Cataract opacification preventing adequate Binocular Indirect Ophthalmoscopic retinal and macular examination.
- Orbital abnormalities, such as thyroid related orbitopathy, causing significant exophthalmos.
- Eyelid abnormalities causing lagophthalmos.
- Significant anterior blepharitis or meibomian gland dysfunction
- Corneal abnormalities or conditions, other than regular topographic corneal astigmatism
- Krukenburg's spindle (linear pigmentary deposits on the corneal endothelium)
- Abnormalities of the iris including trans-illumination defects
- Pupil abnormalities (abnormally shaped, fixed or non-reactive)
- Pharmacologic dilation less than 7 mm
- Axial length <22.5mm
- Lens thickness <4.1 mm
- Anterior chamber depth >2.8mm
- Extremely shallow anterior chamber <2.0mm
- Prior ocular surgery
- Epiretinal membrane
- Macular edema
- Retinal tears including operculated holes
- Amblyopia
- Glaucoma of any kind
- Pseudoexfoliation syndrome
- History of uveitis/iritis
- Diabetic retinopathy
- Acute, chronic or uncontrolled systemic or ocular disease that may confound the results of the study (including rheumatologic conditions such as Rheumatoid arthritis, ankylosing spondyliltis, Sjögren's syndrome, and neurologic conditions such as optic neuritis or multiple sclerosis).
- Prior or anticipated use of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) or similar medications
- Average Keratometry <38D or > 48D by topography
- Any pathology of the zonules including evidence of zonular weakness, zonular instability, zonular damage, or coloboma effecting zonules.
- History of ocular trauma
- Pregnant, lactating, or has another condition with associated fluctuation of hormones that could lead to refractive changes
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Study Eye
Randomized eyes will receive a Gemini IV device in conjunction with an approved monofocal or toric IOL after cataract extraction
|
Eyes randomized to receive the Gemini IV device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
|
ACTIVE_COMPARATOR: Control Eye
control eyes will received an approved monofocal or toric IOL after cataract extraction
|
Control eyes will receive an approved monofocal or toric IOL post cataract extraction
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absence of fusion of peripheral anterior and posterior capsule to the intraocular lens
Time Frame: 6 month postop Visit
|
Via dilated slit lamp examination subjects will be assessed for anterior and posterior fusion of the IOL to the capsular bag with a dichotomous "Yes/No" response.
|
6 month postop Visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
February 21, 2020
Primary Completion (ACTUAL)
August 28, 2020
Study Completion (ACTUAL)
August 28, 2020
Study Registration Dates
First Submitted
August 14, 2019
First Submitted That Met QC Criteria
August 14, 2019
First Posted (ACTUAL)
August 15, 2019
Study Record Updates
Last Update Posted (ACTUAL)
September 16, 2020
Last Update Submitted That Met QC Criteria
September 15, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Gemini IV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cataract
-
Fundación Pública Andaluza para la Investigación...CompletedCataract | Cataract Mature | Cataract, Nuclear
-
Johannes Kepler University of LinzCompletedCataract Complicated | Cataract Complications OperationsAustria
-
Gemini Eye ClinicRecruitingBilateral Cataract | Unilateral CataractCzechia
-
Universitaire Ziekenhuizen KU LeuvenLaboratoires TheaRecruiting
-
Omer Othman AbdullahCompletedCongenital Cataract | Pediatric CataractIraq
-
Johannes Kepler University of LinzRecruitingAphakia | Secondary Cataract Surgery | Complicated Cataract SurgeryAustria
-
Yonsei UniversityCompletedCataract PatientsKorea, Republic of
-
Advanced Center for Eyecare GlobalNot yet recruiting
-
Vienna Institute for Research in Ocular SurgeryRecruiting
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityNot yet recruitingCataract ExtractionChina
Clinical Trials on Gemini IV
-
Neovasc Inc.CompletedAngioplastyUnited States, Canada, Netherlands
-
Abbott Medical DevicesCompleted
-
Federal University of Rio Grande do SulHospital A.C. CamargoRecruitingChildhood Cancer | Chemotherapeutic Toxicity | Oral MucositisBrazil
-
University of Maryland, BaltimoreAstellas Pharma IncTerminated
-
Mansoura UniversityUnknownApical Root Resorption | Labial Alveolar Bone ThicknessEgypt
-
Omega OphthalmicsCompleted
-
Hologic, Inc.Completed
-
Jordan University of Science and TechnologyCompleted
-
Coopervision, Inc.CompletedMyopiaUnited States
-
DMG Dental Material Gesellschaft mbHUniversidad de Concepcion; Universidad de La FronteraCompleted